- Home
- VRNS vs VKTX Comparison
VRNS vs VKTX Comparison
Compare VRNS & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRNS
- VKTX
- Stock Information
- Founded
- VRNS 2004
- VKTX 2012
- Country
- VRNS United States
- VKTX United States
- Employees
- VRNS N/A
- VKTX N/A
- Industry
- VRNS Computer Software: Prepackaged Software
- VKTX Biotechnology: Pharmaceutical Preparations
- Sector
- VRNS Technology
- VKTX Health Care
- Exchange
- VRNS Nasdaq
- VKTX Nasdaq
- Market Cap
- VRNS 5.0B
- VKTX 4.7B
- IPO Year
- VRNS 2014
- VKTX 2015
- Fundamental
- Price
- VRNS $44.19
- VKTX $32.65
- Analyst Decision
- VRNS Buy
- VKTX Strong Buy
- Analyst Count
- VRNS 19
- VKTX 12
- Target Price
- VRNS $59.44
- VKTX $106.75
- AVG Volume (30 Days)
- VRNS 1.4M
- VKTX 4.1M
- Earning Date
- VRNS 02-04-2025
- VKTX 02-05-2025
- Dividend Yield
- VRNS N/A
- VKTX N/A
- EPS Growth
- VRNS N/A
- VKTX N/A
- EPS
- VRNS N/A
- VKTX N/A
- Revenue
- VRNS $546,535,000.00
- VKTX N/A
- Revenue This Year
- VRNS $14.01
- VKTX N/A
- Revenue Next Year
- VRNS $11.83
- VKTX N/A
- P/E Ratio
- VRNS N/A
- VKTX N/A
- Revenue Growth
- VRNS 12.07
- VKTX N/A
- 52 Week Low
- VRNS $41.13
- VKTX $20.75
- 52 Week High
- VRNS $60.58
- VKTX $99.41
- Technical
- Relative Strength Index (RSI)
- VRNS 37.58
- VKTX 25.74
- Support Level
- VRNS $43.88
- VKTX $32.51
- Resistance Level
- VRNS $46.34
- VKTX $43.55
- Average True Range (ATR)
- VRNS 1.26
- VKTX 2.05
- MACD
- VRNS 0.27
- VKTX -0.44
- Stochastic Oscillator
- VRNS 23.35
- VKTX 1.27
About VRNS Varonis Systems Inc.
Varonis Systems is a cybersecurity vendor focused on data privacy and security. The firm is currently undergoing a cloud transition as it weans its on-premises customers over to its cloud products that are delivered as software-as-a-service. The New York-based firm was founded in 2005 and went public in 2014.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.